CJC-1295 (without DAC) vs Proviron
Well Studied vs Well Studied
synergistic Mechanism-based · 60% Proviron helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 (without DAC) Proviron
Weight 3,367.97 Da 304.47 Da
Half-life 30 minutes - 2 hours ~12 hours
Chain 30 amino acids —
Type GHRH analog DHT derivative (C20H32O2)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Proviron
01 Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
02 Improved mood, motivation, confidence, and overall sense of well-being
03 Significant enhancement of libido and sexual function
04 Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
05 Harder, drier, more defined physical appearance without water retention
06 Minimal hepatotoxicity due to absence of 17-alpha alkylation
07 May improve sperm quality at low doses in subfertile men
08 Rapid onset of subjective well-being effects (often within days)
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Proviron
25-75 mg/day / 1-3x per day (oral)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Proviron
Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
Oily skin and increased sebum production
Mild HDL cholesterol suppression with extended use
Increased body hair growth
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Prostate cancer (active or history of androgen-sensitive prostate cancer)
Severe liver impairment (though hepatotoxicity risk is minimal)
Breast cancer in males
Hypersensitivity to mesterolone or any excipients
Women who are pregnant or may become pregnant (androgenic effects on fetus)
Research Evidence
CJC-1295 (without DAC) Proviron
Status Well Studied Well Studied
References 5 studies 5 studies
Latest November 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.